Article
Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Science (New York, N.Y.) - 9 Apr 2010
Zhang Xiao-Wei, Yan Xiao-Jing, Zhou Zi-Ren, Yang Fei-Fei, Wu Zi-Yu, Sun Hong-Bin, Liang Wen-Xue, Song Ai-Xin, Lallemand-Breitenbach Valérie, Jeanne Marion, Zhang Qun-Ye, Yang Huai-Yu, Huang Qiu-Hua, Zhou Guang-Biao, Tong Jian-Hua, Zhang Yan, Wu Ji-Hui, Hu Hong-Yu, de Thé Hugues, Chen Sai-Juan, Chen Zhu
Abstract excerpt
Arsenic, an ancient drug used in traditional Chinese medicine, has attracted worldwide interest because it shows substantial anticancer activity in patients with acute promyelocytic leukemia (APL). Arsenic trioxide (As2O3) exerts its therapeutic effect by promoting degradation of an oncogenic protein that drives the growth of APL cells, PML-RARalpha (a fusion protein containing sequences from the PML zinc finger...
Topics
- Arsenic
- Arsenic Trioxide
- Arsenicals
- Cell Line
- Humans
- Leukemia, Promyelocytic, Acute
- Mutant Proteins
- Mutation
- Nuclear Proteins
- Oncogene Proteins, Fusion